Trending...
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- New Mobile Car Detailing Platform Connects Drivers with On-Demand Local Pros
- Cal State LA secures funding for two artificial intelligence projects from CSU
SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or entities that purchased or otherwise acquired Kiromic Biopharma, Inc. (NASDAQ: KRBP) securities pursuant to the Company's July 2021 initial public offering ("IPO"), or between June 25, 2021 and August 13, 2021, for violations of the Securities Act of 1933 and the Securities Exchange Act of 1934. Kiromic presents itself as a target discovery and gene-editing company that utilizes artificial intelligence to create immunotherapy products.
If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here.
More on The Californer
What is this Case About: Kiromic Biopharma, Inc. (KRBP) Failed To Disclose In Its Offering Documents That The FDA Had Placed A Clinical Hold On Its Two Drug Candidates
According to the complaint, the offering documents in support of the IPO contained untrue statements of material fact. On June 16 and 17, 2021, the Company received communications from the FDA that the FDA was placing the Company's Investigational New Drug Applications for its two candidates on clinical hold. Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021. However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold. When a proposed study is placed on clinical hold, no new subjects may be recruited for testing the drug and patients testing the drug must be taken off.
Next Steps: If you acquired shares of Kiromic Biopharma, Inc. pursuant to the Company's IPO or between June 25, 2021 and August 13, 2021, you have until October 4, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Kiromic Biopharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
If you would like more information about Kiromic Biopharma Inc.'s misconduct, click here.
More on The Californer
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Wise Business Plans Emerges as a Go-To Partner for Angel Investors, VCs, Family Offices and Private
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Neurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY® (crinecerfont) in Adult Patients, at ENDO 2025
- Mike Diamond Offers $775 Off Full Heating & A/C Installation for a Limited Time
What is this Case About: Kiromic Biopharma, Inc. (KRBP) Failed To Disclose In Its Offering Documents That The FDA Had Placed A Clinical Hold On Its Two Drug Candidates
According to the complaint, the offering documents in support of the IPO contained untrue statements of material fact. On June 16 and 17, 2021, the Company received communications from the FDA that the FDA was placing the Company's Investigational New Drug Applications for its two candidates on clinical hold. Rather than disclosing this information, Kiromic represented that clinical testing was expected to proceed in the third quarter of 2021. However, clinical testing did not proceed in the third quarter 2021, nor was it likely given the FDA's imposition of a clinical hold. When a proposed study is placed on clinical hold, no new subjects may be recruited for testing the drug and patients testing the drug must be taken off.
Next Steps: If you acquired shares of Kiromic Biopharma, Inc. pursuant to the Company's IPO or between June 25, 2021 and August 13, 2021, you have until October 4, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
More on The Californer
- Mike Diamond Offers $99 Drain Cleaning to Help Los Angeles Homeowners Save
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Bilingual Children's Book Where Nopalitos Grow Added to Los Angeles Public Library Collection
- Bennett Awards Crafts Prestigious Custom Gold Trophies for VidCon's Inaugural Hall of Fame
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Kiromic Biopharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com
Filed Under: Business
0 Comments
Latest on The Californer
- California: Governor Newsom provides $11 million to organizations helping underserved job seekers find training and employment
- For Artificial Intelligence Appreciation Day: Celebrate it with a poem about AI called "Robot Love"
- City of Long Beach Shares Federal Funding Updates and Local Impacts
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate
- Fortrea Holdings Inc. (FTRE) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Two themes emerge in Marketing AI
- California: Governor Newsom restructures state government to combat homelessness, boost housing and affordability
- Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
- Josh and Heidi Follow Up the Much Anticipated and Successful Launch of the "Spreading the Good BUZZ" Podcast with a Personal Request
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- City of Long Beach Opens Applications for Cannabis Equity Program
- Ridgeback Lighting Launches Battery-Free EBL LED Emergency and Egress Light
- Long Beach: Health Department Announces Certification of 32 Community Violence Intervention Workers
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- First Partner highlights apprenticeship program helping underrepresented youth break into careers in California's iconic entertainment industry
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Cal State LA secures funding for two artificial intelligence projects from CSU
- Colbert Packaging Announces WBENC Recognition